| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
925.03(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,166 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-03-16 |
4 |
AS |
$6.13 |
$214,414 |
D/D |
(35,000) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-03-16 |
4 |
AB |
$4.40 |
$175,250 |
D/D |
35,000 |
83,187 |
|
- |
|
| O Donnell Michael J |
Director |
– • – |
2010-03-11 |
4 |
S |
$6.14 |
$153,608 |
D/D |
(25,000) |
5,775 |
|
- |
|
| Barbier Remi |
CEO and Chair of Board |
• • • |
2010-03-03 |
4 |
AS |
$6.13 |
$33,344 |
D/D |
(5,443) |
6,271,447 |
|
- |
|
| Barbier Remi |
CEO and Chair of the Board |
• • • |
2010-03-02 |
4 |
AS |
$6.13 |
$89,934 |
D/D |
(14,667) |
6,276,890 |
|
- |
|
| Barbier Remi |
CEO and Chair of the Board |
• • • |
2010-03-01 |
4 |
AS |
$6.05 |
$180,706 |
D/D |
(29,890) |
6,291,557 |
|
- |
|
| Barbier Remi |
CEO and Chair of the Board |
• • • |
2010-02-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,600 |
48,375 |
|
- |
|
| Barbier Remi |
CEO and Chair of the Board |
• • • |
2010-02-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
28,800 |
6,321,447 |
|
- |
|
| Barbier Remi |
CEO, President, Chairman of Bd |
• • • |
2010-02-02 |
4 |
AS |
$5.34 |
$107,929 |
D/D |
(20,200) |
6,350,247 |
|
- |
|
| Barbier Remi |
CEO, President, Chairman of Bd |
• • • |
2010-02-01 |
4 |
AS |
$5.30 |
$158,059 |
D/D |
(29,800) |
6,370,447 |
|
- |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2010-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
14,937 |
302,195 |
|
- |
|
| Barbier Remi |
CEO, President and Chairman of |
• • • |
2010-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
27,772 |
6,400,247 |
|
- |
|
| Roddy Peter S |
Director |
– • – |
2010-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,630 |
38,413 |
|
- |
|
| Barbier Remi |
CEO, Chairman of Board |
• • • |
2010-01-06 |
4 |
AS |
$5.40 |
$78,329 |
D/D |
(14,500) |
6,372,475 |
|
- |
|
| Barbier Remi |
CEO, Chairman of Board |
• • • |
2010-01-05 |
4 |
AS |
$5.40 |
$105,918 |
D/D |
(19,600) |
6,386,975 |
|
- |
|
| Barbier Remi |
CEO, Chairman of Board |
• • • |
2010-01-04 |
4 |
AS |
$5.37 |
$85,367 |
D/D |
(15,900) |
6,406,575 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2009-12-07 |
4 |
S |
$5.19 |
$77,835 |
D/D |
(15,000) |
287,258 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2009-11-16 |
4 |
S |
$5.00 |
$75,000 |
D/D |
(15,000) |
302,258 |
|
- |
|
| Barbier Remi |
Chief Executive Officer, |
• • • |
2009-11-05 |
4 |
AS |
$4.80 |
$48,000 |
D/D |
(10,000) |
6,472,475 |
|
- |
|
| Barbier Remi |
Chief Executive Officer, |
• • • |
2009-11-04 |
4 |
AS |
$4.81 |
$72,105 |
D/D |
(15,000) |
6,482,475 |
|
- |
|
| Barbier Remi |
Chief Executive Officer, |
• • • |
2009-11-03 |
4 |
AS |
$4.82 |
$72,330 |
D/D |
(15,000) |
6,497,475 |
|
- |
|
| Barbier Remi |
Chief Executive Officer, |
• • • |
2009-11-02 |
4 |
AS |
$4.93 |
$49,260 |
D/D |
(10,000) |
6,512,475 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2009-10-15 |
4 |
B |
$2.00 |
$100,000 |
D/D |
50,000 |
244,019 |
2.39 |
- |
|
| Barbier Remi |
CEO |
• • • |
2009-10-07 |
4 |
AS |
$5.34 |
$53,430 |
D/D |
(10,000) |
6,522,475 |
|
- |
|
| Barbier Remi |
CEO |
• • • |
2009-10-06 |
4 |
AS |
$5.35 |
$53,470 |
D/D |
(10,000) |
6,532,475 |
|
- |
|
504 Records found
|
|
Page 9 of 21 |
|
|
1.56 (7.24%) 
